NEW YORK, Feb. 07, 2017 -- The Nasdaq Stock Market® (Nasdaq:NDAQ) announced that trading was halted today in Kitov Pharmaceuticals Holdings Ltd. (Nasdaq:KTOV), (Nasdaq:KTOVW) at 09:22:28 Eastern Time for "additional information requested" from the company at a last sale price of $2.55 and $0.89 respectively.
Trading will remain halted until Kitov Pharmaceuticals Holdings Ltd. has fully satisfied Nasdaq’s request for additional information.
For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.
NDAQO
Nasdaq Media Contact: Peter Gau +1.212.231.5475 [email protected]


Instagram Outage Disrupts Thousands of U.S. Users
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Washington Post Publisher Will Lewis Steps Down After Layoffs
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



